Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amy Nelson

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Annals of Internal Medicine|November 4, 2014
Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot studyAnu Osinusi, Anita Kohli, Miriam M Marti, et al.
Respiratory Medicine|July 2, 2013
Vitamin D, vitamin D binding protein, lung function and structure in COPDIsaac Berg, Corrine Hanson, Harlan Sayles, et al.
The Lancet. Infectious Diseases|July 19, 2015
Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort studyAnita Kohli, Rama Kapoor, Zayani Sims, et al.
American Journal of Respiratory Cell and Molecular Biology|October 9, 2012
Attenuation of inhibitory prostaglandin E2 signaling in human lung fibroblasts is mediated by phosphodiesterase 4Joel Michalski, Nobuhiro Kanaji, Xiangde Liu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 2, 2015
Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral RegimensEleanor M Wilson, Sarah Kattakuzhy, Sreetha Sidharthan, et al.
Journal of Inflammation Research|September 25, 2013
Anti-inflammatory effects of budesonide in human lung fibroblast are independent of histone deacetylase 2Xingqi Wang, Amy Nelson, Zachary M Weiler, et al.
Frontiers in Medicine|January 23, 2023
Probable vertical transmission of Alpha variant of concern (B.1.1.7) with evidence of SARS-CoV-2 infection in the syncytiotrophoblast, a case reportHannah A Bullock, Erika Fuchs, Roosecelis B Martines, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|February 4, 2014
Reprogramming of COPD lung fibroblasts through formation of induced pluripotent stem cellsHesham Basma, Yoko Gunji, Shunichiro Iwasawa, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 28, 2015
Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver DiseaseSarah Kattakuzhy, Eleanor Wilson, Sreetha Sidharthan, et al.
Annals of Internal Medicine|November 24, 2015
Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized TrialAnita Kohli, Sarah Kattakuzhy, Sreetha Sidharthan, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Annals of Internal Medicine|November 4, 2014
Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot studyAnu Osinusi, Anita Kohli, Miriam M Marti, et al.
Respiratory Medicine|July 2, 2013
Vitamin D, vitamin D binding protein, lung function and structure in COPDIsaac Berg, Corrine Hanson, Harlan Sayles, et al.
The Lancet. Infectious Diseases|July 19, 2015
Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort studyAnita Kohli, Rama Kapoor, Zayani Sims, et al.
American Journal of Respiratory Cell and Molecular Biology|October 9, 2012
Attenuation of inhibitory prostaglandin E2 signaling in human lung fibroblasts is mediated by phosphodiesterase 4Joel Michalski, Nobuhiro Kanaji, Xiangde Liu, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 2, 2015
Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral RegimensEleanor M Wilson, Sarah Kattakuzhy, Sreetha Sidharthan, et al.
Journal of Inflammation Research|September 25, 2013
Anti-inflammatory effects of budesonide in human lung fibroblast are independent of histone deacetylase 2Xingqi Wang, Amy Nelson, Zachary M Weiler, et al.
Frontiers in Medicine|January 23, 2023
Probable vertical transmission of Alpha variant of concern (B.1.1.7) with evidence of SARS-CoV-2 infection in the syncytiotrophoblast, a case reportHannah A Bullock, Erika Fuchs, Roosecelis B Martines, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|February 4, 2014
Reprogramming of COPD lung fibroblasts through formation of induced pluripotent stem cellsHesham Basma, Yoko Gunji, Shunichiro Iwasawa, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 28, 2015
Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver DiseaseSarah Kattakuzhy, Eleanor Wilson, Sreetha Sidharthan, et al.
Annals of Internal Medicine|November 24, 2015
Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized TrialAnita Kohli, Sarah Kattakuzhy, Sreetha Sidharthan, et al.
Pageof 6